Roadmap for the international collaborative epidemiologic monitoring of safety and effectiveness of new high priority vaccines

Vaccine

Volumn 31, Issue 35, 2013, Pages 3623-3627

  Izurieta, Hector S ^a   Zuber, Patrick ^b   Bonhoeffer, Jan ^c,d   Chen, Robert T ^e   Sankohg, Osman ^f,g,h   Laserson, Kayla F ^k   Sturkenboom, Miriam ^l   Loucq, Christian ⁱ   Weibel, Daniel ^l   Dodd, Caitlin ^j   Black, Steve ^j  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c Brighton Collaboration Foundation   (Switzerland)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f Studies of the Epidemiology of Epilepsy in Demographic Surveillance Systems   (Ghana)

^g UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^h HANOI MEDICAL UNIVERSITY   (Viet Nam)

ⁱ KEMRI CDC Public Health and Research Collaboration   (Kenya)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k International Vaccine Institute   (South Korea)

^l CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

more..

Author keywords

Adverse events; Benefit risk; Effectiveness; Safety; Vaccine

Indexed keywords

ROTAVIRUS VACCINE; VACCINE;

ARTICLE; BRAZIL; CLINICAL EVALUATION; COMMUNICABLE DISEASE; DEMOGRAPHY; DISEASE CONTROL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENDEMIC DISEASE; EPIDEMIOLOGICAL MONITORING; HEALTH CARE PERSONNEL; HOSPITALIZATION; HUMAN; INTERNATIONAL COOPERATION; LOWEST INCOME GROUP; MASS IMMUNIZATION; MEXICO; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; THERAPY EFFECT; VACCINATION; VACCINE FAILURE;

ADVERSE EVENTS; BENEFIT-RISK; EFFECTIVENESS; SAFETY; VACCINE;

COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; EPIDEMIOLOGICAL MONITORING; HUMANS; RISK ASSESSMENT; VACCINATION; VACCINES;

EID: 84880723820     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.05.027     Document Type: Article

References (39)

1. Strom B.L. What is pharmacoepidemiology. Pharmacoepidemiology 2012, Wiley, Chichester, UK. fifth ed. B.L. Strom, S.E. Kimmel, S. Hennessy (Eds.).
2. Ouandaogo C.R., Yaméogo T.M., Diomandé F.V., Sawadogo C., Ouédraogo B., Ouédraogo-Traoré R., et al. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010. Vaccine 2012, 30(May (Suppl. 2)):B46-51. Epub 2012 Jan 9.
3. Graham J.E., Borda-Rodriguez A., Huzair F., Zinck E. Capacity for a global vaccine safety system: the perspective of national regulatory authorities. Vaccine 2012, 30:4953-4959.
4. The Global Alliance for Vaccines and Immunization: http://www.one.org/c/us/policybrief/3260.
5. WHO. Draft Global Vaccine Action Plan (GVAP). http://apps.who.int/gb/ebwha/pdf_files/WHA65/A65_22-en.pdf.
6. Ball R., Horne D., Izurieta H., Sutherland A., Walderhaug M., Hsu H. Statistical, epidemiological, and risk-assessment approaches to evaluating safety of vaccines throughout the life cycle at the Food and Drug Administration. Pediatrics 2011, 127(May (Suppl. 1)):S31-S38.
7. Rashid H., Khandaker G., Booy R. Vaccination and herd immunity: what more do we know?. Curr Opin Infect Dis 2012, 25(June (3)):243-249.
8. Youngkong S., Kapiriri L., Baltussen R. Setting priorities for health interventions in developing countries: a review of empirical studies. Trop Med Int Health 2009, 14(August (8)):930-939. Epub 2009 Jun 26.
9. Draper S.J., Heeney J.L. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 2010, 8:62-73.
10. Gray G., Buchbinder S., Duerr A. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS 2010, 5(September (5)):357-361.
11. Black S., Eskola J., Siegrist C.A., Halsey N., MacDonald N., Andrews N., et al. Importance of background rates of disease in assessment of vaccine safety during mass immunization with pandemic H1N1 influenza vaccines. Lancet 2009, 374:2115-2122.
12. Singleton J.A., Lloyd J.C., Mootrey G.T., Salive M.E., Chen R.T. An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system, VAERS Working Group. Vaccine 1999, 17(22):2908-2917.
13. Varricchio F., Iskander J., Destefano F., Ball R., Pless R., Braun M.M., et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004, 23(4):287-294.
14. Schonberger L.B., Bregman D.J., Sullivan-Bolyai J.Z., Keenlyside R.A., Ziegler D.W., Retailliau H.F., et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979 Aug, 110(2):105-123.
15. Gangarosa E.J., Galazka A.M., Wolfe C.R., Phillips L.M., Gangarosa R.E., Miller E., et al. Impact of anti-vaccine movements on pertussis control: the untold story. Lancet 1998, 351(January (9099)):356-361. PubMed PMID: 9652634.
16. Institute of Medicine (US) Immunization Safety Review Committee. Immunization Safety Review: Vaccines and Autism. Washington (DC): National Academies Press (US); 2004. PubMed PMID: pmid:20669467.
17. Aylward B., Tangermann R. The global polio eradication initiative: lessons learned and prospects for success. Vaccine 2011, 29(December (Suppl. 4)):D80-D85.
18. Hesseling A.C., Marais B.J., Gie R.P., Simon Schaaf H., Fine P.E.M., Godfrey-Faussett P., et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 2007, 25:14-18.
19. Monath T.P. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines 2012 Apr, 11(4):427-448.
20. World Health Organization. Global Vaccine Safety Blueprint (2012). WHO/IVB/12.07; 2012.
21. Patel M.M., Haber P., Baggs J., Zuber P., Bines J.E., Parashar U.D. Intussusception and rotavirus vaccination: a review of the available evidence. Expert Rev Vaccines 2009, 8(November (11)):1555-1564.
22. http://www.who.int/immunization_safety/publications/aefi/en/AEFI_WPRO.pdf.
23. http://www.whale.to/vaccines/dpt1.html.
24. da Silveira C.M., Kmetzsch C.I., Mohrdieck R., Sperb A.F., Prevots D.R. The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997. Int J Epidemiol Oct 2002, 31(5):983-984.
25. Poland G.A., Grabenstein J.D., Neff J.M. The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine 2005, 23:2078-2081. 2005.
26. Ball R., Horne D., Izurieta H.S., Sutherland A., Walderhaug M., Henry H. Statistical, epidemiological, and risk-assessment approaches to evaluating safety of vaccines throughout the life cycle at the Food and Drug Administration. Pediatrics (online) 2011, 10.1542/peds.2010-1722F.
27. Rantala H., Cherry J.D., Shields W.D., Uhari M. Epidemiology of Guillain-Barre syndrome in children: relationship of oral polio vaccine administration to occurrence. J Pediatr 1994, 124:220-223.
28. Sexton K., McNicholas A., Galloway Y., Radke S., Kieft C., Stehr-Green P., et al. Henoch-Schonlein purpura and meningococcal B vaccination. Arch Dis Child 2009, 94:224-226.
29. http://www.indepth-network.org/.
30. Sankoh O., Byass P. The INDEPTH Network: filling vital gaps in global epidemiology. Int J Epidemiol 2012, 41(3):579-588.
31. Dodd C.N., Izurieta H.S., Zuber P., Romio S., Sturkenboom M., Hua W., et al. International collaborative case series safety monitoring for pandemic 2009 H1N1 vaccines: estimation of the risk of Guillain-Barre syndrome. Poster 778. 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management 2012.
32. Whitaker H.J., Farrington C.P., Spiessens B., et al. Tutorial in biostatistics: the self-controlled case series method. Stat Med 2006, 25:1768-1797.
33. Farrington C.P. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics 1995, 51:228-235.
34. Hua W., Sun G., Dodd C.N., Romio S.A., Whitaker H.J., Izurieta H.S., et al. A Simulation study to compare three self-controlled case series approaches: correction for violation of assumption and explanation of bias. Pharmacoepidemiol Drug Saf 2013, (Apr. (29).). in press. 10.1002/pds.3451.
35. Patel M.M., López-Collada V.R., Bulhões M.M., et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med 2011, 364(June (24)):2283-2292.
36. Scheifele D., Morris R., Halperin S., et al. IMPACT monitoring network: a better mousetrap. Can J Infect Dis 1993, 4:75-76.
37. http://www.cdc.gov/vaccinesafety/Activities/vsd.html.
38. Chen R.T., DeStefano F., Davis R.L., et al. The Vaccine Safety Datalink: immunization research in health maintenance organizations in the USA. Bull World Health Organ 2000, 78(2):186-194.
39. Black S. Global Vaccine Safety DataNet meeting. Expert Rev Vaccines 2008, 7(February (1)):15-20.